Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan B Corcoran

Showing results (41-50 of 106) with videos related to

Pageof 11
Sort By:
Oncoimmunology|May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanomaMeghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.
JCO Precision Oncology|October 12, 2023
Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA TestingStefania Napolitano, Aparna R Parikh, Jason Henry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2019
Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal CancerSophia C Kamran, Jochen K Lennerz, Claire A Margolis, et al.
Cancer Discovery|October 4, 2015
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric CancerEunice L Kwak, Leanne G Ahronian, Giulia Siravegna, et al.
The Oncologist|October 31, 2018
Enrichment of <i>HER2</i> Amplification in Brain Metastases from Primary Gastrointestinal MalignanciesDevarati Mitra, Jeffrey W Clark, Helen A Shih, et al.
Cancer Discovery|March 27, 2012
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenibRyan B Corcoran, Hiromichi Ebi, Alexa B Turke, et al.
The Oncologist|April 5, 2021
Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight LossTill Dominik Best, Eric J Roeland, Nora K Horick, et al.
The Oncologist|May 2, 2019
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for TherapyAparna R Parikh, Yuting He, Ted S Hong, et al.
Science Translational Medicine|August 2, 2013
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanomaRyan B Corcoran, Stephen Michael Rothenberg, Aaron N Hata, et al.
Cancer Medicine|May 18, 2018
Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysisSophia C Kamran, Jeffrey W Clark, Hui Zheng, et al.
Pageof 11

Showing results (41-50 of 106) with videos related to

Sort By:
Pageof 11
Oncoimmunology|May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanomaMeghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.
JCO Precision Oncology|October 12, 2023
Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA TestingStefania Napolitano, Aparna R Parikh, Jason Henry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2019
Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal CancerSophia C Kamran, Jochen K Lennerz, Claire A Margolis, et al.
Cancer Discovery|October 4, 2015
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric CancerEunice L Kwak, Leanne G Ahronian, Giulia Siravegna, et al.
The Oncologist|October 31, 2018
Enrichment of <i>HER2</i> Amplification in Brain Metastases from Primary Gastrointestinal MalignanciesDevarati Mitra, Jeffrey W Clark, Helen A Shih, et al.
Cancer Discovery|March 27, 2012
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenibRyan B Corcoran, Hiromichi Ebi, Alexa B Turke, et al.
The Oncologist|April 5, 2021
Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight LossTill Dominik Best, Eric J Roeland, Nora K Horick, et al.
The Oncologist|May 2, 2019
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for TherapyAparna R Parikh, Yuting He, Ted S Hong, et al.
Science Translational Medicine|August 2, 2013
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanomaRyan B Corcoran, Stephen Michael Rothenberg, Aaron N Hata, et al.
Cancer Medicine|May 18, 2018
Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysisSophia C Kamran, Jeffrey W Clark, Hui Zheng, et al.
Pageof 11